Menu

Details of First Three-Parent IVF Revealed

The team that oversaw the first use of mitochondrial replacement therapy that resulted in a live birth has published an account of the procedure.

Apr 3, 2017
Bob Grant

John Zhang with the baby that was the first ever to be born after mitochondrial replacement therapyIMAGE COURTESY OF NEW HOPE FERTILITY CLINIC

Last year, a Jordanian couple became parents to the world’s first-ever baby born through a controversial in vitro fertilization (IVF) technique called mitochondrial replacement therapy (MRT). Now, the doctors who performed the procedure, which involves inserting nuclei from the mothers’ egg cells and into donor ova with healthy mitochondria, have revealed more detail on the conception and resulting live birth. 

John Zhang of the New Hope Fertility Center in New York City and colleagues published an account of the treatment in this month’s issue of Reproductive BioMedicine Online. “Certainly, this is a landmark study,” Dietrich Egli, a stem cell researcher at the New York Stem Cell Foundation, told Nature.

Zhang and colleagues revealed that the mother of the baby boy is a carrier of Lehigh disease, a rare neurometabolic disorder that decimates a child’s muscular system and often results in respiratory failure and death. The authors also described the IVF procedure, including the method they used to transfer the mother’s egg cell nuclei into the donor egg cells. They froze and heated the embryo and then fused the mother’s nuclei into donor ova using an electrical pulse.

In their paper, the researchers also reported that the child carried a 2.36 percent to 9.23 percent mitochondrial DNA (mtDNA) mutational load in samples tested (including hair follicles, circumcised foreskin, and umbilical blood). Because some mutated mtDNA slipped into the embryo, the child may suffer health problems later in life, the authors wrote.

The parents of the child told Zhang and colleagues that they would forgo any mitochondrial testing in their son unless it becomes medically necessary.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.